Elan offers Tysabri dividend after Royalty approach

[riky]

Elan offers Tysabri dividend after Royalty approach

DUBLIN (Reuters) - Irish drugmaker Elan said it will give shareholders 20 percent of the royalty rights for multiple sclerosis drug Tysabri in a bid to stave off an approach for the company by U.S. investment firm Royalty Pharma . New York-based Royalty made its $6.6 billion approach last week, just two weeks after Elan announced it had sold its 50 percent interest in Tysabri for $3.25 billion plus future royalty payments to U.S. partner Biogen Idec . ...

Source: You are not allowed to view links. Register or Login